Downregulation of <i>SUMO2</i> inhibits hepatocellular carcinoma cell proliferation, migration and invasion

Chen, Jintu; Chen, Canwei; Lin, Yongfa; Su, Yongfa; Yu, Xueping; Jiang, Yancheng; Chen, Zixuan; Ke, Shao-Ying; Lin, Shaoze; Chen, LiangJuan; Zhang, Zhishan; Zhang, Tao

doi:10.1002/2211-5463.13173

Cited by 6 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, literature cites SUMO2/3 as a pivotal agent driving colorectal cancer progression and oxaliplatin resistance by orchestrating the sumoylation modification of the DNA assembly constituent, Ku80 [56] . Recent revelations align with our experimental evidence, advocating that SUMO2 exerts a positive regulatory influence on hepatocellular carcinoma progression [ 57 , 58 ]. Concurrently, sumoylation modifications have been firmly established as regulators of CSC stemness [ 15 , 17 ].…”

Section: Discussionsupporting

confidence: 66%

FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness

Peng,

Wang,

Wen

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 66%

FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness

Peng,

Wang,

Wen

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…This observation aligns with a study by Chen et al, which demonstrated increased SUMO2 mRNA expression levels in liver cancer tissues compared with adjacent tissues. [34] Another previous study also showed that SUMO2 is upregulated and contributes to regulate the cell cycle in HCC. [35] Using siRNA to knock down SUMO2 expression, the authors showed that downregulation of SUMO2 may inhibit the proliferation, clone formation, and invasive ability of liver cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Expression of SUMO and NF-κB genes in hepatitis B virus-associated hepatocellular carcinoma patients: An observational study

Khai,

Huy,

Trang

et al. 2024

Medicine

View full text Add to dashboard Cite

Alterations in signaling pathways and modulation of cell metabolism are associated with the pathogenesis of cancers, including hepatocellular carcinoma (HCC). Small ubiquitin-like modifier (SUMO) proteins and NF-κB family play major roles in various cellular processes. The current study aims to determine the expression profile of SUMO and NF-κB genes in HCC tumors and investigate their association with the clinical outcome of HCC. The expression of 5 genes – SUMO1, SUMO2, SUMO3, NF-κB p65, and NF-κB p50 – was quantified in tumor and adjacent non-tumor tissues of 58 HBV-related HCC patients by real-time quantitative PCR and was analyzed for the possible association with clinical parameters of HCC. The expression of SUMO2 was significantly higher in HCC tumor tissues compared to the adjacent non-tumor tissues (P = .01), while no significant difference in SUMO1, SUMO3, NF-κB p65, and NF-κB p50 expression was observed between HCC tumor and non-tumor tissues (P > .05). In HCC tissues, a strong correlation was observed between the expression of SUMO2 and NF-κB p50, between SUMO3 and NF-κB p50, between SUMO3 and NF-κB p65 (Spearman rho = 0.83; 0.82; 0.772 respectively; P < .001). The expression of SUMO1, SUMO2, SUMO3, NF-κB p65, and NF-κB p50 was decreased in grade 3 compared to grades 1 and 2 in HCC tumors according to the World Health Organization grades system. Our results highlighted that the SUMO2 gene is upregulated in tumor tissues of patients with HCC, and is related to the development of HCC, thus it may be associated with the pathogenesis of HCC.

show abstract

“… 3 , 20 In particular, higher expression of the genes involved in SUMOylation had been earlier detected as a pattern shared among patients with an accelerated progression of HCC. 21 To date, the upregulation of SUMO1, 22 SUMO2, 23 SAE1, 24 UBA2, 25 UBC9, 26 – 29 PIAS1, 30 PIAS2, 31 PIAS4, 32 , 33 SENP1, 34 – 36 SENP5, 37 SENP6, 38 , 39 and SENP7 40 in HCC and their value either as diagnostic or prognostic biomarkers have been described. Conversely, SENP2 expression is decreased in HCC and might play a role as a tumor suppressor.…”

Section: Introductionmentioning

confidence: 99%

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

Lachiondo-Ortega,

Rejano-Gordillo,

Simon

et al. 2024

Cell Reports

View full text Add to dashboard Cite

Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion

Abstract: FEBS Open Bio (2021) ª 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.SUMO2 promotes HCC progression J. Chen et al.

Cited by 6 publications

References 41 publications

FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness

FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness

Expression of SUMO and NF-κB genes in hepatitis B virus-associated hepatocellular carcinoma patients: An observational study

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

Contact Info

Product

Resources

About